Lumexa Imaging (LMRI) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Smith & Nephew SNATS is the larger company by market cap ($11.28 billion vs $992.5 million), about 11.4 times the size. On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 11.6x for Lumexa Imaging). Smith & Nephew SNATS pays a dividend yielding 1.47%, while Lumexa Imaging does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMRI | SNN |
|---|---|---|
| Share price | $10.33 | $26.96 |
| Market cap | $992.45M | $11.28B |
| 1-day change | -2.46% | +0.26% |
| YTD return | -44.16% | -17.83% |
| 1-year return | — | -24.97% |
| 5-year return | — | -23.82% |
| P/E ratio (TTM) | — | 18.34 |
| Forward P/E | 11.61 | 11.18 |
| EPS (TTM) | $-0.37 | $1.47 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | — | $6.16B |
| Revenue growth (YoY) | — | +6.09% |
| Net income (latest FY) | — | $625.00M |
| Gross margin | — | 68.01% |
| Operating margin | — | 12.88% |
| Net margin | — | 10.14% |
| 52-week high | $19.45 | $37.51 |
| 52-week low | $6.45 | $26.12 |
| Distance from 52-week high | -46.89% | -28.13% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +71.06% | +19.88% |
| Average volume | 430.76K | 1.65M |
| Shares outstanding | 96.07M | 418.52M |
| Employees | 5,000 | 17,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Smith & Nephew SNATS is about 11.4 times larger than Lumexa Imaging by market value ($11.28B vs $992.45M).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
About Lumexa Imaging
LMRI stock →Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.
Healthcare · Medical Devices · 5,000 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Healthcare · Medical Devices · 17,000 employees
LMRI vs SNN FAQ
Which is bigger, Lumexa Imaging or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.28B compared with $992.45M for Lumexa Imaging (LMRI).
Which pays a higher dividend, Lumexa Imaging or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while Lumexa Imaging does not currently pay a regular dividend.
Are Lumexa Imaging and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.